{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:45Z","timestamp":1790384325646,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00981-5","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:22:54Z","timestamp":1783768974000},"page":"2359-2375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Practical Guide to Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy"],"prefix":"10.1007","volume":"15","author":[{"given":"Johannes","family":"Jakobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kuitwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"5","key":"981_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.27709","volume":"66","author":"JA Allen","year":"2022","unstructured":"Allen JA, Lewis RA. Treatment of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2022;66(5):552\u20137. https:\/\/doi.org\/10.1002\/mus.27709.","journal-title":"Muscle Nerve"},{"issue":"3","key":"981_CR2","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s13311-022-01221-y","volume":"19","author":"LA Querol","year":"2022","unstructured":"Querol LA, Hartung HP, Lewis RA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics. 2022;19(3):864\u201373. https:\/\/doi.org\/10.1007\/s13311-022-01221-y.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"981_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","volume":"7","author":"MC Dalakas","year":"2011","unstructured":"Dalakas MC. Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507\u201317. https:\/\/doi.org\/10.1038\/nrneurol.2011.121.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"981_CR4","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","volume":"268","author":"L Querol","year":"2021","unstructured":"Querol L, Crabtree M, Herepath M, et al. Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol. 2021;268(10):3706\u201316. https:\/\/doi.org\/10.1007\/s00415-020-09998-8.","journal-title":"J Neurol"},{"issue":"3","key":"981_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst. 2021;26(3):242\u201368. https:\/\/doi.org\/10.1111\/jns.12455.","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"981_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/mus.27038","volume":"62","author":"KL Gable","year":"2020","unstructured":"Gable KL, Attarian H, Allen JA. Fatigue in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;62(6):673\u201380. https:\/\/doi.org\/10.1002\/mus.27038","journal-title":"Muscle Nerve"},{"issue":"9","key":"981_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","volume":"86","author":"EK Mathey","year":"2015","unstructured":"Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973\u201385. https:\/\/doi.org\/10.1136\/jnnp-2014-309697.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"981_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","volume":"102","author":"Y Rodriguez","year":"2019","unstructured":"Rodriguez Y, Vatti N, Ramirez-Santana C, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8\u201337. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.021.","journal-title":"J Autoimmun"},{"issue":"1","key":"981_CR9","doi-asserted-by":"publisher","first-page":"CD010369","DOI":"10.1002\/14651858.CD010369.pub2","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1(1):CD010369. https:\/\/doi.org\/10.1002\/14651858.CD010369.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"981_CR10","doi-asserted-by":"publisher","first-page":"CD003906","DOI":"10.1002\/14651858.CD003906.pub4","volume":"2015","author":"MM Mehndiratta","year":"2015","unstructured":"Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):CD003906. https:\/\/doi.org\/10.1002\/14651858.CD003906.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"981_CR11","doi-asserted-by":"publisher","first-page":"CD002062","DOI":"10.1002\/14651858.CD002062.pub4","volume":"11","author":"RA Hughes","year":"2017","unstructured":"Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;11(11):CD002062. https:\/\/doi.org\/10.1002\/14651858.CD002062.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"981_CR12","doi-asserted-by":"publisher","first-page":"CD001797","DOI":"10.1002\/14651858.CD001797.pub4","volume":"2","author":"SR Bus","year":"2024","unstructured":"Bus SR, de Haan RJ, Vermeulen M, van Schaik IN, Eftimov F. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2024;2(2):CD001797. https:\/\/doi.org\/10.1002\/14651858.CD001797.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"981_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/ITT.S388151","volume":"13","author":"YA Rajabally","year":"2024","unstructured":"Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy: current therapeutic approaches and future outlooks. Immunotargets Ther. 2024;13:99\u2013110. https:\/\/doi.org\/10.2147\/ITT.S388151.","journal-title":"Immunotargets Ther"},{"issue":"6","key":"981_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/mus.23843","volume":"48","author":"L Querol","year":"2013","unstructured":"Querol L, Rojas-Garcia R, Casasnovas C, et al. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve. 2013;48(6):870\u20136. https:\/\/doi.org\/10.1002\/mus.23843.","journal-title":"Muscle Nerve"},{"issue":"1","key":"981_CR15","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.1038\/s41598-020-64699-6","volume":"10","author":"L Gentile","year":"2020","unstructured":"Gentile L, Mazzeo A, Russo M, Arimatea I, Vita G, Toscano A. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Sci Rep. 2020;10(1):7910. https:\/\/doi.org\/10.1038\/s41598-020-64699-6.","journal-title":"Sci Rep"},{"issue":"7","key":"981_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/jnnp-2014-310280","volume":"87","author":"D Cocito","year":"2016","unstructured":"Cocito D, Merola A, Romagnolo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87(7):791\u20133. https:\/\/doi.org\/10.1136\/jnnp-2014-310280.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"981_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ene.12080","volume":"20","author":"LH Markvardsen","year":"2013","unstructured":"Markvardsen LH, Debost JC, Harbo T, Debost J-C, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20(5):836\u201342. https:\/\/doi.org\/10.1111\/ene.12080.","journal-title":"Eur J Neurol"},{"issue":"1","key":"981_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(17)30378-2.","journal-title":"Lancet Neurol"},{"issue":"3","key":"981_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/jns.12573","volume":"28","author":"V Bril","year":"2023","unstructured":"Bril V, Hadden RDM, Brannagan TH 3rd, et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst. 2023;28(3):436\u201349. https:\/\/doi.org\/10.1111\/jns.12573.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"981_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1756285616679369","volume":"10","author":"G Ellrichmann","year":"2017","unstructured":"Ellrichmann G, Gold R, Ayzenberg I, Yoon MS, Schneider-Gold C. Two years\u2019 long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. Ther Adv Neurol Disord. 2017;10(2):91\u2013101. https:\/\/doi.org\/10.1177\/1756285616679369.","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"981_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/jnnp-2014-309042","volume":"86","author":"K Kuitwaard","year":"2015","unstructured":"Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA. Intravenous immunoglobulin response in treatment-naive chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2015;86(12):1331\u20136. https:\/\/doi.org\/10.1136\/jnnp-2014-309042.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"981_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/mus.27820","volume":"68","author":"A Al-Zuhairy","year":"2023","unstructured":"Al-Zuhairy A, Jakobsen J. Outcome in chronic inflammatory demyelinating polyneuropathy: a systematic review and meta-analysis. Muscle Nerve. 2023;68(4):388\u201396. https:\/\/doi.org\/10.1002\/mus.27820.","journal-title":"Muscle Nerve"},{"issue":"10","key":"981_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","volume":"23","author":"JA Allen","year":"2024","unstructured":"Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024;23(10):1013\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(24)00309-0.","journal-title":"Lancet Neurol"},{"key":"981_CR24","unstructured":"US Food and Drug Administration. VYVGART\u00ae HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761304s005,s006lbl.pdf (accessed February 3, 2026)."},{"key":"981_CR25","doi-asserted-by":"publisher","first-page":"123313","DOI":"10.1016\/j.jns.2024.123313","volume":"468","author":"T Levine","year":"2025","unstructured":"Levine T, Muley S. Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment. J Neurol Sci. 2025;468:123313. https:\/\/doi.org\/10.1016\/j.jns.2024.123313.","journal-title":"J Neurol Sci"},{"key":"981_CR26","doi-asserted-by":"publisher","first-page":"123354","DOI":"10.1016\/j.jns.2024.123354","volume":"468","author":"C Karam","year":"2025","unstructured":"Karam C. Navigating the switch from IVIG to FcRn inhibition in CIDP: clinical insights. J Neurol Sci. 2025;468:123354. https:\/\/doi.org\/10.1016\/j.jns.2024.123354.","journal-title":"J Neurol Sci"},{"issue":"9","key":"981_CR27","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/jnnp-2023-333112","volume":"95","author":"L Querol","year":"2024","unstructured":"Querol L, De S\u00e8ze, Dysgaard T, et al. Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study. J Neurol Neurosurg Psychiatry. 2024;95(9):845\u201354. https:\/\/doi.org\/10.1136\/jnnp-2023-333112.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"981_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1468-1331.2006.01278.x","volume":"13","author":"RA Hughes","year":"2006","unstructured":"Hughes RA, Bouche P, Cornblath DR, et al. European federation of neurological societies\/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society. Eur J Neurol. 2006;13(4):326\u201332. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01278.x.","journal-title":"Eur J Neurol"},{"issue":"3","key":"981_CR29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/cpj.0000000000001150","volume":"12","author":"C Karam","year":"2022","unstructured":"Karam C. Chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Clin Pract. 2022;12(3):258\u201362. https:\/\/doi.org\/10.1212\/cpj.0000000000001150.","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"981_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PY Van den Bergh","year":"2010","unstructured":"Van den Bergh PY, Hadden RD, Bouche P, et al. European federation of neurological societies\/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society\u2014first revision. Eur J Neurol. 2010;17(3):356\u201363. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02930.x.","journal-title":"Eur J Neurol"},{"issue":"1","key":"981_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mus.24088","volume":"50","author":"A Breiner","year":"2014","unstructured":"Breiner A, Brannagan TH. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2014;50(1):40\u20136. https:\/\/doi.org\/10.1002\/mus.24088.","journal-title":"Muscle Nerve"},{"key":"981_CR32","unstructured":"Lucke IM, van Doorn P, Vrancken A, Eftimov F. Spierziekten Centrum Nederland chronische inflammatoire demyeliniserende polyneuropathie (CIDP) national protocol. 2023. Available from: https:\/\/www.spierziektencentrum.nl\/richtlijn\/landelijk-protocol-voor-onderhoudsbehandeling-intraveneus-immunoglobuline-ivig-in-chronische-inflammatoire-demyeliniserende-polyneuropathie-cidp\/ (accessed February 3, 2026)."},{"key":"981_CR33","unstructured":"Medicinr\u00e5det. Medicinr\u00e5dets behandlingsvejledning vedr\u00f8rende immunglobuliner til behandling af kronisk inflammatorisk demyeliniserende polyneuropati (CIDP)\u2014version 1.2. 2024. Available from: https:\/\/medicinraadet-dk.b-cdn.net\/media\/cxzc2da3\/medicinradets-beh-vejl-vedr-immunglobuliner-til-kronisk-inflammatorisk-demyeliniserende-polyneuropati-cidp-vers-1-2.pdf (accessed February 3, 2026)."},{"issue":"8","key":"981_CR34","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.neurol.2023.03.010","volume":"179","author":"P Cintas","year":"2023","unstructured":"Cintas P, Bouhour F, Cauquil C, et al. Current clinical management of CIDP with immunoglobulins in France: an expert opinion. Revue Neurologique. 2023;179(8):914\u201322. https:\/\/doi.org\/10.1016\/j.neurol.2023.03.010.","journal-title":"Revue Neurologique"},{"issue":"1","key":"981_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jns.12158","volume":"21","author":"MP Lunn","year":"2016","unstructured":"Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MMA. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripheral Nerv Syst. 2016;21(1):33\u20137. https:\/\/doi.org\/10.1111\/jns.12158.","journal-title":"J Peripheral Nerv Syst"},{"issue":"9","key":"981_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neurol.2022.06.004","volume":"178","author":"G Fargeot","year":"2022","unstructured":"Fargeot G, Gitiaux C, Magy L, et al. French recommendations for the management of adult & pediatric chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Revue Neurologique. 2022;178(9):953\u201368. https:\/\/doi.org\/10.1016\/j.neurol.2022.06.004.","journal-title":"Revue Neurologique"},{"issue":"4","key":"981_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.clinph.2020.12.017","volume":"132","author":"A Al-Zuhairy","year":"2021","unstructured":"Al-Zuhairy A, Jakobsen J, Krarup C. Early axonal loss predicts long-term disability in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2021;132(4):1000\u20137. https:\/\/doi.org\/10.1016\/j.clinph.2020.12.017.","journal-title":"Clin Neurophysiol"},{"issue":"1","key":"981_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00415-024-12860-w","volume":"272","author":"A Schumacher","year":"2025","unstructured":"Schumacher A, Hieke A, Spenner M, et al. Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry. J Neurol. 2025;272(1):100. https:\/\/doi.org\/10.1007\/s00415-024-12860-w.","journal-title":"J Neurol"},{"issue":"3","key":"981_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jns.12344","volume":"24","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Blomkwist-Markens PH, Horemans A, van Doorn PA, Jacobs BC. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):253\u20139. https:\/\/doi.org\/10.1111\/jns.12344.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"981_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/mus.26772","volume":"61","author":"A Al-Zuhairy","year":"2020","unstructured":"Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020;61(3):316\u201324. https:\/\/doi.org\/10.1002\/mus.26772.","journal-title":"Muscle Nerve"},{"issue":"9","key":"981_CR41","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1007\/s00415-024-12548-1","volume":"271","author":"P Quint","year":"2024","unstructured":"Quint P, Schroeter CB, Kohle F, et al. Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort. J Neurol. 2024;271(9):5930\u201343. https:\/\/doi.org\/10.1007\/s00415-024-12548-1.","journal-title":"J Neurol"},{"key":"981_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/trf.14479","volume":"58","author":"TS Ipe","year":"2018","unstructured":"Ipe TS, Marques MB. Vascular access for therapeutic plasma exchange. Transfusion. 2018;58:580\u20139. https:\/\/doi.org\/10.1111\/trf.14479.","journal-title":"Transfusion"},{"key":"981_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-338140","author":"SRM Bus","year":"2026","unstructured":"Bus SRM, van Doorn IN, Zambreanu L, et al. Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2026. https:\/\/doi.org\/10.1136\/jnnp-2025-338140.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"981_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jns.12608","volume":"29","author":"LS Kodal","year":"2024","unstructured":"Kodal LS, Witt AM, Pedersen BS, Aagaard MM, Dysgaard T. Prognostic value of neurofilament light in blood in patients with polyneuropathy: a systematic review. J Peripher Nerv Syst. 2024;29(1):17\u201327. https:\/\/doi.org\/10.1111\/jns.12608.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"981_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3810\/pgm.2013.03.2619","volume":"125","author":"R Broyles","year":"2013","unstructured":"Broyles R, Rodden L, Riley P, Berger M. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders. Postgrad Med. 2013;125(2):65\u201372. https:\/\/doi.org\/10.3810\/pgm.2013.03.2619.","journal-title":"Postgrad Med"},{"issue":"2","key":"981_CR46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(07)70329-0.","journal-title":"Lancet Neurol"},{"issue":"12","key":"981_CR47","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/jnnp.2010.206599","volume":"81","author":"K Kuitwaard","year":"2010","unstructured":"Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2010;81(12):1374\u20139. https:\/\/doi.org\/10.1136\/jnnp.2010.206599.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"981_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/jns.12161","volume":"21","author":"F Gallia","year":"2016","unstructured":"Gallia F, Balducci C, Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies. J Peripher Nerv Syst. 2016;21(2):82\u20134. https:\/\/doi.org\/10.1111\/jns.12161.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"981_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00415-018-9157-4","volume":"266","author":"YA Rajabally","year":"2019","unstructured":"Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019;266(2):461\u20137. https:\/\/doi.org\/10.1007\/s00415-018-9157-4.","journal-title":"J Neurol"},{"issue":"3","key":"981_CR50","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awab422","volume":"145","author":"DR Cornblath","year":"2022","unstructured":"Cornblath DR, van Doorn PA, Hartung HP, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;145(3):887\u201396. https:\/\/doi.org\/10.1093\/brain\/awab422.","journal-title":"Brain"},{"issue":"7","key":"981_CR51","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/archneurol.2010.105","volume":"67","author":"N Latov","year":"2010","unstructured":"Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802\u20137. https:\/\/doi.org\/10.1001\/archneurol.2010.105.","journal-title":"Arch Neurol"},{"issue":"5","key":"981_CR52","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/brain\/awac054","volume":"145","author":"M Adrichem","year":"2022","unstructured":"Adrichem M, Lucke I, Vrancken A, et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;145(5):1641\u201352. https:\/\/doi.org\/10.1093\/brain\/awac054.","journal-title":"Brain"},{"issue":"5","key":"981_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3233\/JND-221615","volume":"10","author":"LK Markvardsen","year":"2023","unstructured":"Markvardsen LK, Sindrup SH, Christiansen I, Sheikh AM, Holbech JV, Andersen H. Standardized tapering off subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. J Neuromuscul Dis. 2023;10(5):787\u201396. https:\/\/doi.org\/10.3233\/JND-221615.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"981_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/jns.12303","volume":"24","author":"O Mielke","year":"2019","unstructured":"Mielke O, Bril V, Cornblath DR, et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre-randomization phase of the polyneuropathy and treatment with hizentra study. J Peripher Nerv Syst. 2019;24(1):72\u20139. https:\/\/doi.org\/10.1111\/jns.12303.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"981_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","volume":"38","author":"JA Allen","year":"2021","unstructured":"Allen JA, Butler L, Levine T, Haudrich A. A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy. Adv Ther. 2021;38(1):316\u201328. https:\/\/doi.org\/10.1007\/s12325-020-01540-6.","journal-title":"Adv Ther"},{"issue":"6","key":"981_CR56","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/ene.14796","volume":"28","author":"MC Broers","year":"2021","unstructured":"Broers MC, Bunschoten C, Drenthen J, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2021;28(6):2065\u201373. https:\/\/doi.org\/10.1111\/ene.14796.","journal-title":"Eur J Neurol"},{"issue":"6","key":"981_CR57","first-page":"254","volume":"124","author":"AE Baars","year":"2023","unstructured":"Baars AE, Jacobs BC, Wirtz PW, Venhovens J, van Doorn PA, Kuitwaard K. Het onderscheid tussen chronische inflammatoire demyeliniserende polyneuropathie en \u2018mimics\u2019 in de klinische praktijk (Distinguishing chronic inflammatory demyelinating polyneuropathy and mimics in clinical practice). Tijdschr Neurol Neurochir. 2023;124(6):254\u20139.","journal-title":"Tijdschr Neurol Neurochir"},{"key":"981_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TCRM.S360249","volume":"20","author":"IN van Doorn","year":"2024","unstructured":"van Doorn IN, Eftimov F, Wieske L, van Schaik IN, Verhamme C. Challenges in the early diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in adults: current perspectives. Ther Clin Risk Manag. 2024;20:111\u201326. https:\/\/doi.org\/10.2147\/TCRM.S360249.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"981_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/jns.12502","volume":"27","author":"MC Broers","year":"2022","unstructured":"Broers MC, de Wilde M, Lingsma HF, van der Lei J, Verhamme KMC, Jacobs BC. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in the Netherlands. J Peripher Nerv Syst. 2022;27(3):182\u20138. https:\/\/doi.org\/10.1111\/jns.12502.","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"981_CR60","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00415-017-8578-9","volume":"264","author":"E Spina","year":"2017","unstructured":"Spina E, Topa A, Iodice R, et al. Early predictive factors of disability in CIDP. J Neurol. 2017;264(9):1939\u201344. https:\/\/doi.org\/10.1007\/s00415-017-8578-9.","journal-title":"J Neurol"},{"issue":"6","key":"981_CR61","doi-asserted-by":"publisher","first-page":"e209130","DOI":"10.1212\/WNL.0000000000209130","volume":"102","author":"Y Aotsuka","year":"2024","unstructured":"Aotsuka Y, Misawa S, Suichi T, et al. Prevalence, clinical profiles, and prognosis of CIDP in Japanese nationwide survey: analyses of 1,257 diagnosis-confirmed patients. Neurology. 2024;102(6):e209130. https:\/\/doi.org\/10.1212\/WNL.0000000000209130.","journal-title":"Neurology"},{"issue":"4","key":"981_CR62","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/00207454.2020.1815733","volume":"132","author":"M Kapoor","year":"2022","unstructured":"Kapoor M, Reilly MM, Manji H, Lunn MP, Aisling S. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies. Int J Neurosci. 2022;132(4):352\u201361. https:\/\/doi.org\/10.1080\/00207454.2020.1815733.","journal-title":"Int J Neurosci"},{"issue":"10","key":"981_CR63","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/00207454.2016.1269328","volume":"127","author":"R Debs","year":"2017","unstructured":"Debs R, Reach P, Cret C, et al. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients. Int J Neurosci. 2017;127(10):864\u201372. https:\/\/doi.org\/10.1080\/00207454.2016.1269328.","journal-title":"Int J Neurosci"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00981-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00981-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:02:45Z","timestamp":1790380965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00981-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00981-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Johannes Jakobsen has received payment or honoraria for lectures, presentations, or educational events from Takeda. Chafic Karam has received grants or contracts from Ionis and Argenx in the past 36 months and consultancy fees from Alexion, Alnylam, Alpine, Amgen, Amicus, Annexon, Argenx, AstraZeneca, Biogen, Corino, CSL Behring, Genentech, Ionis, J&J, Neuroderm, Novo Nordisk, Octapharma, Pfizer, Sanofi, Takeda, UCB, Vertex, and Zai Lab. Krista Kuitwaard has received research grants from Albert Schweitzer Hospital, Takeda, and the For Wis(h)dom Foundation in the past 36 months, consultancy fees from Takeda, speakers fees from Grifols and Octapharma, and support for attending meetings and travel from GBS-CIDP Foundation International and Octapharma. Todd Levine is a consultant for FFF Enterprises and is on the speakers bureau for Grifols.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}